{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:04:04Z","timestamp":1789167844848,"version":"build-2803163510"},"reference-count":21,"publisher":"Georg Thieme Verlag KG","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n            Funktion von SGLT2-Inhibitoren und pathophysiologische Effekte Natrium-Glukose-Co-Transporter-2-Inhibitoren (SGLT2) k\u00f6nnen die Glukose-Reabsorption im proximalen Tubulus blockieren und spielen damit eine wichtige Rolle in der Zuckerkontrolle beim Diabetes mellitus.<\/jats:p><jats:p>\n            Erweiterung des Einsatzgebietes von SGLT2 Zus\u00e4tzlich zur glukosurischen Wirkung wurden eher \u00fcberraschend sehr umfangreiche, weitere positive Effekte bei chronischen Nierenfunktionsst\u00f6rungen beobachtet. Auch zeigte sich eine starke kardioprotektive Wirkung bei der Herzinsuffizienz. Mittlerweile wurden zahlreiche Mechanismen abseits der reinen zuckerbeeinflussenden Wirkung der SGLT2-Inhibitioren identifiziert, die sowohl das Herz als auch die Niere direkt positiv beeinflussen k\u00f6nnen.<\/jats:p>","DOI":"10.1055\/a-1971-3381","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T23:50:23Z","timestamp":1698969023000},"page":"1456-1461","source":"Crossref","is-referenced-by-count":1,"title":["SGLT2-Inhibitoren f\u00fcr Herz und Niere"],"prefix":"10.1055","volume":"148","author":[{"given":"Markus","family":"van der Giet","sequence":"additional","affiliation":[{"name":"Medizinische Klinik mit Schwerpunkt Nephrologie und Internistische Intensivmedizin, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"issue":"36","key":"ref1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"TA McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"S 05","key":"ref2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","author":"Disease Kidney","year":"2022","journal-title":"Kidney Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003480.","article-title":"2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH)","author":"G Mancia Chairperson","year":"2023","journal-title":"J Hypertens"},{"issue":"07","key":"ref4","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2174\/138920011796504509","article-title":"Kidney in diabetes: from organ damage target to therapeutic target","volume":"12","author":"T Salvatore","year":"2011","journal-title":"Curr Drug Metab"},{"issue":"04","key":"ref5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"SD Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"ref6","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"B Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"07","key":"ref7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"B Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"06","key":"ref8","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s00125-021-05407-5","article-title":"Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial","volume":"64","author":"DZI Cherney","year":"2021","journal-title":"Diabetologia"},{"issue":"07","key":"ref9","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.3390\/ijms23073651","article-title":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","volume":"23","author":"T Salvatore","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1056\/NEJMoa2204233","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","journal-title":"Lancet"},{"issue":"04","key":"ref11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"C Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"ref12","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"V Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"02","key":"ref13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease","volume":"384","author":"DL Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"ref14","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"HJL Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"WG Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"21","key":"ref16","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"JJV McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"ref17","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"M Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"ref18","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.jacc.2023.03.390","article-title":"Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories","volume":"81","author":"J Butler","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"ref19","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"SD Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"ref20","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"SD Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"02","key":"ref21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","volume":"384","author":"DL Bhatt","year":"2021","journal-title":"N Engl J Med"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1971-3381.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T23:51:40Z","timestamp":1698969100000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1971-3381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":21,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2023,11,2]]},"published-print":{"date-parts":[[2023,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1971-3381","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}